JP2022531929A5 - - Google Patents

Info

Publication number
JP2022531929A5
JP2022531929A5 JP2021566455A JP2021566455A JP2022531929A5 JP 2022531929 A5 JP2022531929 A5 JP 2022531929A5 JP 2021566455 A JP2021566455 A JP 2021566455A JP 2021566455 A JP2021566455 A JP 2021566455A JP 2022531929 A5 JP2022531929 A5 JP 2022531929A5
Authority
JP
Japan
Prior art keywords
composition according
lipids
bams
pharmaceutical composition
biocides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032039 external-priority patent/WO2020231786A1/en
Publication of JP2022531929A publication Critical patent/JP2022531929A/ja
Publication of JP2022531929A5 publication Critical patent/JP2022531929A5/ja
Pending legal-status Critical Current

Links

JP2021566455A 2019-05-10 2020-05-08 バイオフィルム関連肺状態を処置するための組成物および方法 Pending JP2022531929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962846084P 2019-05-10 2019-05-10
US62/846,084 2019-05-10
PCT/US2020/032039 WO2020231786A1 (en) 2019-05-10 2020-05-08 Compositions and methods for treating biofilm-related lung conditions

Publications (2)

Publication Number Publication Date
JP2022531929A JP2022531929A (ja) 2022-07-12
JP2022531929A5 true JP2022531929A5 (https=) 2023-04-24

Family

ID=73046991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566455A Pending JP2022531929A (ja) 2019-05-10 2020-05-08 バイオフィルム関連肺状態を処置するための組成物および方法

Country Status (13)

Country Link
US (2) US11890341B2 (https=)
EP (1) EP3958869A4 (https=)
JP (1) JP2022531929A (https=)
KR (1) KR20210154872A (https=)
CN (1) CN114080236A (https=)
AU (1) AU2020276206A1 (https=)
BR (1) BR112021022632A2 (https=)
CA (1) CA3138922A1 (https=)
CR (1) CR20210618A (https=)
IL (1) IL287961A (https=)
MX (1) MX2021013663A (https=)
SG (1) SG11202112387UA (https=)
WO (1) WO2020231786A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
CN113873883A (zh) * 2019-03-15 2021-12-31 轨迹Ip有限责任公司 用于生物膜的强化治疗和预防的材料和方法
US20210069276A1 (en) * 2019-09-09 2021-03-11 LiquidPro Ltd. Ear spray device and ear protection composition for preventing water related ear canal disorders
US12334224B2 (en) * 2020-04-14 2025-06-17 Siemens Healthineers Ag Cardiovascular assessment of patients suspected of having COVID-19
US20230070870A1 (en) * 2021-09-09 2023-03-09 Robert V. West, III Covid Nasal Spray
BR102022016098A2 (pt) * 2022-08-12 2024-02-20 Universidade Estadual De Campinas Formulação antiviral e intranasal
CN115400105B (zh) * 2022-10-12 2023-08-22 湖北省农业科学院畜牧兽医研究所 焦棓酸在制备抗马链球菌兽疫亚种药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63182029A (ja) 1987-01-22 1988-07-27 Agency Of Ind Science & Technol リポソ−ム
EP0540074A1 (en) 1991-10-09 1993-05-05 ENIRICERCHE S.p.A. Cloning and sequencing of that chromosomal DNA region of bacillus subtilis comprising the SRFA operon which encodes the multienzymatic complex surfactin synthetase
JP2003246717A (ja) 2002-02-22 2003-09-02 Lion Corp 口腔用組成物
MXPA05013340A (es) 2003-06-09 2006-03-09 Nastech Pharm Co Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
WO2009090656A2 (en) 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
CA2760248C (en) 2009-04-30 2019-05-28 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
EA037276B1 (ru) * 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
MX2014009103A (es) 2012-01-27 2015-11-18 Gfs Corp Aus Pty Ltd Métodos para producir biosurfactantes.
JP2014034552A (ja) * 2012-08-09 2014-02-24 Kao Corp バイオフィルム形成抑制剤
CN103007287A (zh) 2012-09-29 2013-04-03 湖州紫金生物科技有限公司 一种鼠李糖脂作为药物口服促吸收剂的应用
US9585903B2 (en) * 2013-09-30 2017-03-07 Council Of Scientific & Industrial Research Pharmaceutical composition comprising sophorolipid in combination with an antibiotic
US20170014437A1 (en) * 2014-04-03 2017-01-19 Syracuse University Synthetic disugar hydrocarbons as natural analogs to control microbial behaviors
CA2943049A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
WO2015156904A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
US20170304411A1 (en) * 2014-10-24 2017-10-26 Hprd - Health Products Research And Development Lda Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
WO2018049182A2 (en) * 2016-09-08 2018-03-15 Locus Solutions, Llc Distributed systems for the efficient production and use of microbe-based compositions

Similar Documents

Publication Publication Date Title
JP2022531929A5 (https=)
JP6426696B2 (ja) 呼吸器疾患の治療のための方法および製剤
US11890341B2 (en) Compositions and methods for treating biofilm-related lung conditions
JP2016513688A5 (https=)
Zahmatkesh et al. Effect of samarium oxide nanoparticles on virulence factors and motility of multi-drug resistant Pseudomonas aeruginosa
CN102724983A (zh) 雾化左氧氟沙星治疗囊性纤维化的用途
Elkin et al. Pseudomonal infection in cystic fibrosis: the battle continues
CN104602672A (zh) 用于治疗细菌感染的定制脂质体
Stockmann et al. Clinical pharmacokinetics of inhaled antimicrobials
WO2018177218A1 (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
US20240173343A9 (en) Aminoglycoside potentiation for treatment of pulmonary bacterial infection
Wood et al. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia
JP2024009968A5 (https=)
BR112019027255A2 (pt) método para reduzir infecção de pulmão
US20240397944A1 (en) Methods for biofilm disruption
WO2016148066A1 (ja) 呼吸器感染症治療剤
JP2005504095A (ja) モノバクタム組成物およびその使用方法
JP2022512580A5 (https=)
WO2004075874A1 (en) Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
Ottaviano et al. Burkholderia cepacia complex isolation in non-polypoid chronic rhinosinusitis
CN100519533C (zh) 5-芳胺喹啉-7,8-二酮类衍生物及其在制备抗菌药物中的应用
US20180008598A1 (en) Antibacterial nasal compositions and related methods
WO2026060500A1 (en) Method of treating or inhibiting the development of an infection
WO2021205074A1 (en) Inhalable formulation
Grasemann L-Arginine deficiency in cystic fibrosis lung disease